Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.

Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of Type 2 Diabetes (T2DM), which requires daily subcutaneous administration. In T2DM patients, GLP-1 administration is reported to reduce glycaemia and HbA1c in association with a modest, but significan...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Giovanni Di Pasquale, Ilaria Dicembrini, Laura Raimondi, Claudio Pagano, Josephine M Egan, Andrea Cozzi, Lorenzo Cinci, Andrea Loreto, Maria E Manni, Silvia Berretti, Annamaria Morelli, Changyu Zheng, Drew G Michael, Mario Maggi, Roberto Vettor, John A Chiorini, Edoardo Mannucci, Carlo M Rotella
Format:	article
Langue:	EN
Publié:	Public Library of Science (PLoS) 2012
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/b5a58b6ba4de46ae91ab1ee5fd254e6b
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.

Documents similaires